Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nausea 5Vomiting 4Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Weight Loss 1Radiation Injuries 1Neoplasms, Germ Cell and Embryonal 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Anorexia Nervosa with Significantly Low Body Weight 1Anorexia 1

Interventions

Megestrol Acetate 4Mirtazapine 2ostarine 1nabiximols 1clazakizumab 1anamorelin 1Sodium Chloride 1Physical Therapy Modalities 1Omacor 1Olanzapine 1Nutrition Assessment 1Megestrol 1Infliximab 1Ibuprofen 1Gemcitabine 1Flurandrenolone 1Fecal Microbiota Transplantation 1Cyproheptadine 1Clarithromycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cachexia × Olanzapine × Clear all
NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡